RhumbLine Advisers’s Oramed Pharmaceuticals ORMP Stock Holding History

RhumbLine Advisers’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,830	Closed	-$4.7K	–	4294
2024 Q2	$4.7K	Hold	1,830	–	–	﹤0.01%	4095
2024 Q1	$5.34K	Hold	1,830	–	–	﹤0.01%	3974
2023 Q4	$4.23K	Hold	1,830	–	–	﹤0.01%	4011
2023 Q3	$4.78K	Hold	1,830	–	–	﹤0.01%	3988
2023 Q2	$6.55K	Buy	+1,830	New	+$5.87K	﹤0.01%	4037
2022 Q2	–	Sell	-34,046	Closed	-$294K	–	3197
2022 Q1	$294K	Buy	34,046 +9,611	+39%	+$98.5K	﹤0.01%	2649
2021 Q4	$349K	Buy	24,435 +2,212	+10%	+$46.2K	﹤0.01%	2659
2021 Q3	$488K	Buy	22,223 +8,241	+59%	+$140K	﹤0.01%	2552
2021 Q2	$187K	Buy	+13,982	New	+$160K	﹤0.01%	2928

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

RhumbLine Advisers's ORMP Position: Q3 2024 in Review

RhumbLine Advisers sold out of Oramed Pharmaceuticals (ORMP) in Q3 2024, closing a stake of 1,830 shares — an estimated $4.7K sold.

RhumbLine Advisers first reported a position in ORMP in Q2 2021 and held it in 9 quarters. The position peaked at $488K in Q3 2021. 55 funds tracked by Wall St. Rank hold ORMP as of Q3 2024.

RhumbLine Advisers reported no remaining Oramed Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
RhumbLine Advisers sold 1,830 Oramed Pharmaceuticals shares in Q3 2024, an estimated $4.7K.
RhumbLine Advisers first reported a position in Oramed Pharmaceuticals in Q2 2021 and held it in 9 quarters.
RhumbLine Advisers's Oramed Pharmaceuticals position peaked at $488K in Q3 2021.
55 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.